Seth Pollack, MD

Sarcoma Program Director
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Seth Pollack is Director of the Sarcoma Program at Northwestern University's Lurie Cancer Center and the Steven T. Rosen Professor of Cancer Biology at Northwestern's Feinberg School of Medicine. The Pollack lab is developing novel immunotherapeutic approaches to treating sarcoma while using cutting edge technologies to characterize the sarcoma immune microenvironment. Dr. Pollack has led multiple investigator iniated clinical trials and Northwestern is consistently a high enrolling center for sarcoma clinical trials in the US.

Poster(s):

• (P 96) LEPTOMENINGEAL RECURRENCE OF EWING'S SARCOMA: A CASE SERIES

• (P 112) PHASE 1/2 STUDY OF YH001, A CTLA-4 ANTIBODY WITH THE SUBCUTANEOUSLY ADMINISTERED PD-L1 ANTIBODY ENVAFOLIMAB, WITH OR WITHOUT DOXORUBICIN IN PATIENTS WITH ADVANCED OR METASTATIC SOFT TISSUE SARCOMA

• (P 180) HEALTH RELATED QUALITY OF LIFE OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA AND OTHER SOFT TISSUE SARCOMAS TREATED WITH CABOZANTINIB AND TEMOZOLOMIDE

• (P 206) A SINGLE-ARM, PHASE II STUDY OF NEOADJUVANT PEMBROLIZUMAB COMBINED WITH RADIOTHERAPY IN THE PRIMARY TREATMENT OF SOFT TISSUE SARCOMAS.

• (P 219) ELECTIVE DISCONTINUATION OF SORAFENIB TREATMENT IN DESMOID TUMORS: A RETROSPECTIVE ANALYSIS WITH IMPLICATIONS FOR CLINICAL PRACTICE